diagnosis and treatment of valvular heart...
TRANSCRIPT
![Page 1: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/1.jpg)
Computed Tomography - From basics to
clinical use
Diagnosis and Treatment of
Valvular Heart Disease
David Messika-Zeitoun
![Page 2: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/2.jpg)
Disclosures
Lectures fees for Edwards, Abbott
Consultant fees from Symetis
![Page 3: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/3.jpg)
You know what?
Echo is tough …
![Page 4: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/4.jpg)
Planimetry
![Page 5: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/5.jpg)
Transoephageal Echocardiography
TEE
![Page 6: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/6.jpg)
Computed Tomography Planimetry
CT scan
Iodine contrast agent
ECG-gating
Mid-late systolic image
reconstruction
![Page 7: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/7.jpg)
Example of Planimetry of the Aortic Valve Area
Laissy, Heart 2007
![Page 8: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/8.jpg)
Aortic Valve Area
Feuchtner, JACC 2006
![Page 9: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/9.jpg)
Planimetry of Aortic Valve Area
AV
A-M
DC
T (
cm
2)
AVA-Echocardiography (cm2)
0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1 1.1 1.2 1.3 1.4
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
1.1
1.2
1.3
1.4
1.5
-0.8
-0.6
-0.4
-0.2
0.0
0.2
0.4
0.6
0.8
0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1.1 1.2 1.3 1.4
Dif
fere
nc
e (
AV
A-M
DC
T,
AV
A-E
ch
oca
rdio
gra
ph
y )
(cm
2)
Mean (AVA-MDCT, AVA-Echocardiography ) (cm2)
Laissy, Heart 2007
![Page 10: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/10.jpg)
Aortic Valve Area - Results
N AVA echo
(cm2)
AVA CT
(cm2)
Correlation
Coefficient
SD of the
difference (cm2)
Feuchtner 30 0.90±0.22
0.6 – 1.7
0.94±0.27
0.6 – 1.7
0.89 0.13
Bouvier 30 0.80±0.27 0.87±0.33 - 0.16
Alkadhi 20 0.83±0.33
0.4 – 1.6
0.89±0.35
0.44 – 1.53
0.95 0.10
Laissy 40 0.81±0.20
0.35 - 1.2
0.87±0.23
0.40 - 1.45
0.77 0.15
Pouleur 48 2.0±1.5
0.5 – 6.1
2.5±1.7
0.5 – 6.3
0.96 0.5
Lembecke 36 0.74±0.28
0.3 – 1.6
0.88±0.39
0.3 – 2.0
0.91 0.18
<
![Page 11: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/11.jpg)
Aortic Valve Area - Results
36 patients with AS
CT = 0.88±0.39 cm²
TEE = 0.94 ± 0.41 cm²
TTE = 0.74 ± 0.28 cm²
CATH = 0.75 ± 0.31 cm²
Lembcke 2009 Invest Radiol
Effective area
Anatomic area
![Page 12: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/12.jpg)
Aortic Valve
Calcifications
![Page 13: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/13.jpg)
Aortic Valve Calcification (AVC)
Aortic valve calcification (AVC) Coronary artery calcification (AVC)
CT is ideally suited to objectively
and quantitatively assessed calcifications
![Page 14: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/14.jpg)
CT scanner - Acquisition
Forty 3-mm-thick contiguous
transverse slices with 3-mm
table incrementation
Covering the ascending aorta
to the apex
Acquisition triggered by
electrocardiography at 80% of
the RR interval (prospective
ECG-gating)
2 independent runs
No contrast agent
![Page 15: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/15.jpg)
CT Scanner – Measurements of Calcifications
Automated
operator-
independent
image-processing
software
Calcification are
defined as 4
adjacent pixels
with density 130
Hounsfield units
Radiologist affect
the selected area
to the coronary
arteries, the aortic
valve….
![Page 16: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/16.jpg)
The Agatston Score
For each region of interrest, score = density score * area
Total score: sum of score of each region of interest in all
slices
Hn X Factor
130-199 1
200-299 2
300-399 3
> 400 4
Peak density score
Area 1 = 15 mm²
Peak CT = 350 Hn
Area 1 = 30 mm²
Peak CT = 500 Hn
Region 1. Score = 15 * 3 = 45
Region 2. Score = 30 * 4 = 120
![Page 17: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/17.jpg)
Definition of AVC
Aortic valve
calcifications are
defined as
calcifications within
valve leaflets, aortic
annulus, or aortic wall
immediately adjacent
to leaflet or annular
calcification.
![Page 18: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/18.jpg)
Examples of degree of AVC
Mild AVC. Score = 200 AU Moderate AVC. score = 800
Severe AVC. Score = 2000
LA
LV
RV
RA
RA
RV
LA
LV
Mitral
Valve
RV
RA
LA
LV
![Page 19: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/19.jpg)
EB
CT
(s
co
re)
Weight calcium (mg)
0
1000
2000
3000
4000
5000
0 500 1000 1500 2000 2500 3000 3500
r=0.96, p <0.0001
Anatomic validation for AVC
30 valves specimen
Quantification AVC
EBCT (Agatston score)
Tissue digestion
![Page 20: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/20.jpg)
Echocardiographic Evaluation of Aortic Valve Calcifications
None
Mild: isolated spots
Moderate: Multiples
spots
Severe : Large and
diffuse calcifications
![Page 21: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/21.jpg)
Echocardiographic Evaluation of Aortic Valve Calcifications
%
0
10
20
30
40
50
60
70
-1 class Identical +1 class
Classification subjective and inaccurate
![Page 22: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/22.jpg)
(A) Mild calcification of the left coronary cusp (Volume 74 mm3, aortic valve area 2.4 cm²).
(B) Severe calcification (Volume 5044 mm3, aortic valve area 0.4 cm²)
![Page 23: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/23.jpg)
Ao
rtic
va
lve
are
a, cm
2
EBCT Score
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
0 1000 2000 3000 4000 5000 6000 7000 8000
R=-0.79, p<0.0001 R=0.86, p<0.0001
Pe
ak
ao
rtic
va
lve
ve
loc
ity,
m/s
ec
EBCT Score
0 1000 2000 3000 4000 5000 6000 7000 8000 0
1
2
3
4
5
6
7
AVC and Hemodynamic Severity
Messika-Zeitoun Circulation 2004
![Page 24: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/24.jpg)
EBCT Thresholds S
en
sit
ivit
y
1 - Specificity
0.00
0.10
0.20
0.30
0.40
0.50
0.60
0.70
0.80
0.90
1.00
.00 .10 .20 .30 .40 .50 .60 .70 .80 .90 1.00
Score = 500
AUC=0.89
Score = 1100
Score = 2000
![Page 25: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/25.jpg)
Volumetric Assessment
Morghan-Hughes Heart 2003
![Page 26: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/26.jpg)
EBCT = MSCT ?
![Page 27: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/27.jpg)
![Page 28: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/28.jpg)
0.5
1
1.5
2
2.5
3 A
bso
lute
AV
A
0 1000 3000 5000 7000 9000 AVC
0.1
0,.3
0.5
0.7
0.9
1.1
1.3
1.5
Ad
just
ed A
VA
0 1000 3000 5000 7000 9000
AVC
0 10 20 30 40 50 60 70 80 90
100 110 120
Mea
n g
rad
ien
t
0 1000 3000 5000 7000 9000
AVC
0
100
200
300
400
500
600
700
Pea
k v
elo
city
0 1000 3000 5000 7000 9000
AVC Cueff Heart 2011
![Page 29: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/29.jpg)
Sen
sib
ilit
y
0,00
0,10
0,20
0,30
0,40
0,50
0,60
0,70
0,80
0,90
1,00
0,00 0,20 0,40 0,60 0,80 1,00
1-Specificity
Sen
sib
ilit
y
0,00
0,10
0,20
0,30
0,40
0,50
0,60
0,70
0,80
0,90
1,00
0,00 0,20 0,40 0,60 0,80 1,00
1-Specificity
Sen
sib
ilit
y
0,00
0,10
0,20
0,30
0,40
0,50
0,60
0,70
0,80
0,90
1,00
0,00 0,20 0,40 0,60 0,80 1,00
1-Specificity
Sen
sib
ilit
y
0,00
0,10
0,20
0,30
0,40
0,50
0,60
0,70
0,80
0,90
1,00
0,00 0,20 0,40 0,60 0,80 1,00
1-Specificity
AVA : AUC=0.86 AVAi : AUC=0.9
MPG: AUC=0.92 MPV : AUC=0.9
700 AU
1651 AU
2000 AU
2000 AU
1651 AU
2000 AU
1651 AU
2000 AU
1651 AU
700 AU
700 AU
700 AU
![Page 30: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/30.jpg)
Scanner MSCT Thresholds
Calcium
Score
Sensitivity, % Specificity, % PPV, % NPV, %
500 100 31 46 100
700 98 49 49 98
1000 94 65 55 94
1200 91 65 59 92
1651 82 80 70 88
2000 62 86 72 79
3000 57 91 74 72
![Page 31: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/31.jpg)
Clinical Implications
Discrepancies between symptoms
and echocardiographic measurements
Poor echogenicity
Low gradient – low output
![Page 32: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/32.jpg)
Contractile reserve
Final AVA < 1 cm2
AVA increase < 0.3 cm2
Dobutamine
up to 20 μg/kg/min
Contractile reserve
Final AVA > 1 cm2
AVA increase 0.3 cm2
No contractile reserve
(SV increase < 20%)
Severe AS Pseudo-severe AS Non conclusive test
Monin Circulation; 108: 319-324
Low Gradient – Low Output
![Page 33: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/33.jpg)
47 patients with Low EF
EF ≤ 40%
47 patients
MG > 40 mmHg
AVA < 1 cm²
Severe AS
24 patients
MG ≤ 40 mmHg
AVA < 1 cm²
Low gradient / Low Output
20 patients
Severe AS
14 patients
Non Conclusive AS
2 patient
Pseudo Severe AS
4 patients
MG ≤ 40mmHg
AVA ≥ 1 cm²
Non Severe AS
5 patients
Cueff Heart 2011
![Page 34: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/34.jpg)
Koos Radiology 2006
![Page 35: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/35.jpg)
Prognostic value of AVC Echocardiographic assessment
Eve
nt
fre
e s
urv
iva
l (%
) No or mild calcification
Moderate or severe
calcification
P<0.0001
0
20
40
60
80
100
0 1 2 3 4 5 Years Rosenhek NEJM 2000
![Page 36: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/36.jpg)
Prognostic value of AVC EBCT assessment
AVC < 500 AU
AVC 500 AU
P=0.0002
0
20
40
60
80
100
0 1 2 3 4 5
Eve
nt
fre
e s
urv
iva
l (%
)
Years Messika-Zeitoun Circulation 2004
AVC and hemodynamic severity provide
complementary prognostic information
![Page 37: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/37.jpg)
Ao
rtic
va
lve
are
a, cm
2
EBCT Score
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
0 1000 2000 3000 4000 5000 6000 7000 8000
R=-0.79, p<0.0001 R=0.86, p<0.0001
Pe
ak
ao
rtic
va
lve
ve
loc
ity,
m/s
ec
EBCT Score
0 1000 2000 3000 4000 5000 6000 7000 8000 0
1
2
3
4
5
6
7
AVC and Hemodynamic Severity are Not Equivalent
Messika-Zeitoun Circulation 2004
![Page 38: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/38.jpg)
Valve Anatomy
![Page 39: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/39.jpg)
Scanner Bicuspid vs. Tricuspid
Alkhadi, Radiology 2006 Bouvier, EHJ 2006
![Page 40: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/40.jpg)
Transcatheter
Aortic Valve
Implantation (TAVI)
![Page 41: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/41.jpg)
Vascular Access
![Page 42: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/42.jpg)
Safety Issue
![Page 43: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/43.jpg)
The Aortic Annulus is not a Ring …
Anderson Multimedia Manual of Cardiothoracic Surgery 2006
![Page 44: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/44.jpg)
![Page 45: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/45.jpg)
Ovale Shape
Coronal view: 26±3 mm Sagittal view : 24±3 mm
![Page 46: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/46.jpg)
Aorta
Left atrium
A
C
B D
![Page 47: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/47.jpg)
Annulus
Diameter
vs. TTE vs. TEE
P R P R
ECHOCARDIOGRAPHY
TTE 23.9±2.1 - - 0.13 0.89
TEE 24.1±2.1 0.13 0.89 - -
CT
PLAN BASAL
Long axis 27.5±3.1 <0.0001 0.69 <0.0001 0.67
Short axis 21.7±2.3 <0.0001 0.73 <0.0001 0.69
Mean 24.6±2.4 0.004 0.80 0.07 0.77
3 CAVITY 23.8±2.6 0.73 0.71 0.26 0.70
![Page 48: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/48.jpg)
Implantation Strategy
Aortic annulus diameter
18 21 25
23 mm Prosthesis 26 mm Prosthesis
![Page 49: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/49.jpg)
Strategy of implantation Agreement
with TTE
Agreement
with TEE
23 mm
Prosthesis
26 mm
Prosthesis
No
implantation
% Kappa % Kappa
Echography
TTE 5 29 11 - - 83% 0.68
TEE 6 25 14 83% 0.68 - -
CT
BASAL
Long axis 0 10 35 36% 0.03 42% 0.07
Short axis 16 21 8 47% 0.13 42% 0.09
Mean 4 24 17 62% 0.32 62% 0.34
3 CAVITY 7 25 13 60% 0.28 58% 0.27
![Page 50: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/50.jpg)
![Page 51: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/51.jpg)
Comprehensive
Evaluation
of AS
![Page 52: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/52.jpg)
CT Coronary Angiography
Mollet JACC 2004
![Page 53: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/53.jpg)
CT Coronary Angiography in AS
Gilard Reant Laissy
N of patients 55 40 40
Prevalence of coronary stenosis
(coronary angiogram)
20 32.5 33
Sensibility, % 100 85 85
Specificity, % 80 78 93
Positive predictive value, % 55 67 85
Negative predictive value, % 100 96 93
![Page 54: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/54.jpg)
CT MRI
Juergens Radiology 2004
Left Ventricular Volumes and Ejection Fraction
![Page 55: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/55.jpg)
Comprehensive Evaluation
Aortic Valve Area Coronary arteries Ejection fraction
![Page 56: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/56.jpg)
Mitral
Stenosis
![Page 57: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/57.jpg)
Mitral Valve Area
29 patients
Sinus Rhythm
MVAECHO :
1.44±0.53 cm2
(0.7- 2.3)
Early diastole
![Page 58: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/58.jpg)
MVA – Experienced Operator
0.6
0.8
1.0
1.2
1.4
1.6
1.8
2.0
2.2
2.4
2.6
0.6 0.8 1.0 1.2 1.4 1.6 1.8 2 2.2 2.4 2.6
MV
A-C
T (
cm
2)
MVA-ECHO (cm2)
Dif
fere
nc
e (
MV
A-C
T,
MV
A-E
CH
O)
(cm
2)
Mean (MVA-CT, MVA-ECHO) (cm2)
-1.0
-0.8
-0.6
-0.4
-0.2
0.0
0.2
0.4
0.6
0.8
1.0
0.6 0.8 1.0 1.2 1.4 1.6 1.8 2.0 2.2 2.4 2.6
Messika-Zeitoun, JACC 2006
![Page 59: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/59.jpg)
Examples
![Page 60: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/60.jpg)
MVA – Non-experienced Operator
MV
A, cm
2
CT
non-experienced
CT
experienced
2D
experienced
1.45±0.55 1.47±0.49 1.38±0.52
P = 0.25
P=0.70
1.10
1.20
1.30
1.40
1.00
1.50
0.6
0.8
1
1.2
1.4
1.6
1.8
2
2.2
2.4
2.6
2.8
0.6 0.8 1 1.2 1.4 1.6 1.8 2 2.2 2.4 2.6 2.8
MV
A-C
T (
cm
2)
MVA-ECHO (cm2)
![Page 61: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/61.jpg)
Work in
Progress
![Page 62: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/62.jpg)
Alkhadi, Radiology 2005
Mitral Insufficiency
![Page 63: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/63.jpg)
Aortic Insufficiency
Alkhadi, Radiology 2005
![Page 64: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/64.jpg)
Limits
Image Quality
Exclusion of patients in AF
Reference method debatable: semi-quantitative echocardiography
or angiography
Thresholds
FEUCHTNER AJR 2008 Alkhadi, Radiology 2007
![Page 65: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/65.jpg)
Prosthetic Valves
![Page 66: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/66.jpg)
Infective Endocarditis
![Page 67: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/67.jpg)
Conclusion
Calcium Scoring in patients in low gradient low ejection fraction
TAVI
Aortic Valve Area
CT coronary angiography
Ejection fraction
Mitral valve area
Mitral and aortic insufficiency , Prosthesis, Infective
endocarditis?
Seconde Line Examination
First Line Examination
![Page 68: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures](https://reader031.vdocument.in/reader031/viewer/2022011801/5b0191d37f8b9ab9598c8852/html5/thumbnails/68.jpg)
Thank You